Onchilles Pharma, founded on groundbreaking research into a novel neutrophil pathway, is dedicated to revolutionizing cancer treatment. The company's core mission is to develop first-in-class pan-cancer therapeutics that leverage innate immuno-biology. Their innovative approach aims to create medicines that can selectively and comprehensively kill cancer cells, regardless of genetic background, anatomical origin, or immunotype. Onchilles Pharma focuses on global drug discovery and development to bring these next-generation therapies to market.
Notable affiliated individuals and investors include leading scientists and biotech investors committed to advancing cancer treatment. The company has achieved significant milestones in preclinical studies, demonstrating the potential of their novel mechanism of action. Onchilles Pharma's impact lies in its promise to offer a universal cancer treatment solution, potentially transforming the oncology landscape and providing new hope for patients worldwide.
